Measures of adherence to epilepsy treatment: Review of present practices and recommendations for future directions

Epilepsia

Volumn 49, Issue 7, 2008, Pages 1115-1122

  Paschal, Angelia M ^a   Hawley, Suzanne R ^a   Romain, Theresa St ^a   Ablah, Elizabeth ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

Epilepsy; Patient adherence; Treatment principles

Indexed keywords

CLINICAL EVALUATION; CULTURAL FACTOR; DRUG BLOOD LEVEL; DRUG HAIR LEVEL; DRUG MONITORING; EPILEPSY; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; READING; REVIEW; SALIVA ANALYSIS; SEIZURE; SELF REPORT;

ANTICONVULSANTS; COGNITION; CULTURE; EPILEPSY; FORECASTING; GUIDELINE ADHERENCE; HAIR; HEALTH BEHAVIOR; HUMANS; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; SALIVA;

EID: 47249108971     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01645.x     Document Type: Review

References (67)

1. Adamolekun B, Mielke JK, Ball DE 1999) An evaluation of the impact of health worker and patient education on the care and compliance of patients with epilepsy in Zimbabwe. Epilepsia 40 : 507 511.
2. Affolter N, Krahenbuhl S, Schlienger RG 2003) Appropriateness of serum level determinations of antiepileptic drugs. Swiss Med Wkly 133 : 591 597.
3. Al-Faris EA, Abdulghani HM, Mahdi AH, Salih MA, Al-Kordi AG 2002) Compliance with appointments and medications in a pediatric neurology clinic at a University Hospital in Riyadh, Saudi Arabia. Saudi Med J 23 : 969 974.
4. Azrin NH, Teichner G 1998) Evaluation of an instructional program for improving medication compliance for chronically mentally ill outpatients. Behav Res Ther 36 : 849 861.
5. Ball DE, Taderera A 2003) Development of drug use indicators for epilepsy. Cent Afr J Med 49 : 134 138.
6. Baumann RJ, Ryan M, Yelowitz A 2004) Physician preference for antiepileptic drug concentration testing. Pediatr Neurol 30 : 29 32.
7. Buelow JM, Smith MC 2004) Medication management by the person with epilepsy: perception versus reality. Epilepsy Behav 5 : 401 406.
8. Chappell B 1992) Epilepsy: patient views on their condition and treatment. Seizure 1 : 103 109.
9. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL 1989) How often is medication taken as prescribed? A novel assessment technique. JAMA 261 : 3273 3277.
10. Cramer JA, Scheyer RD, Mattson RH 1990) Compliance declines between clinic visits. Arch Intern Med 150 : 1509 1510.
11. Cramer JA, Westbrook LE, Devinsky O, Perrine K, Glassman MB, Camfield C 1999) Development of the quality of life in epilepsy inventory for adolescents: the QOLIE-AD-48. Epilepsia 40 : 1114 1121.
12. DiIorio C, Henry M 1995) Self-management in persons with epilepsy. J Neurosci Nurs 27 : 338 343.
13. DiIorio C, Yeager K, Shafer PO, Letz R, Henry T, Schomer DL, McCarty F 2003) The epilepsy medication and treatment complexity index: reliability and validity testing. J Neurosci Nurs 35 : 155 162.
14. Dutta S, Reed RC 2006) Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. J Clin Pharm Ther 31 : 321 329.
15. Fisher RS, Vickrey BG, Gibson P, Hermann B, Penovich P, Scherer A, Walker SG 2000) The impact of epilepsy from the patient's perspective II: views about therapy and health care. Epilepsy Res 41 : 53 61.
16. Golbeck AL, Ahlers-Schmidt CR, Paschal AM, Dismuke SE 2005) A definition and operational framework for health numeracy. Am J Prev Med 29 : 375 376.
17. Gomes MDM, Maia Filho HDS 1998) Medication-taking behavior and drug self regulation in people with epilepsy. Arquivos de Neuro-psiquiatria 56 : 714 719.
18. Gomes MDM, Maia Filho HDS, Noe RA 1998) Anti-epileptic drug intake adherence. The value of the blood drug level measurement and the clinical approach. Arquivos de Neuro-psiquiatria 56 : 708 713.
19. Goulle JP, Noyon J, Layet A, Rapoport NF, Vaschalde Y, Pignier Y, Bouige D, Jouen F 1995) Phenobarbital in hair and drug monitoring. Forensic Sci Int 70 : 191 202.
20. Graves NM, Holmes GB, Leppik IE 1988) Compliant populations: variability in serum concentrations. Epilepsy Res Suppl 1 : 91 99.
21. Grim SA, Ryan M, Miles MV, Tang PH, Strawsburg RH, deGrauw TJ, Fakhoury TA, Baumann RJ 2003) Correlation of levetiracetam concentrations between serum and saliva. Ther Drug Monit 25 : 61 66.
22. Hazzard A, Hutchinson SJ, Krawiecki N 1990) Factors related to adherence to medication regimens in pediatric seizure patients. J Pediatr Psychol 15 : 543 555.
23. Helgeson DC, Mittan R, Tan SY, Chayasirisobhon S 1990) Sepulveda Epilepsy Education: the efficacy of a psychoeducational treatment program in treating medical and psychosocial aspects of epilepsy. Epilepsia 31 : 75 82.
24. Herkes GK, Eadie MJ 1990) Possible roles for frequent salivary antiepileptic drug monitoring in the management of epilepsy. Epilepsy Res 6 : 146 154.
25. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R 2007) How common are the "common" neurologic disorders? Neurology 68 : 326 337.
26. Jones RM, Butler JA, Thomas VA, Peveler RC, Prevett M 2006) Adherence to treatment in patients with epilepsy: associations with seizure control and illness beliefs. Seizure 15 : 504 508.
27. Kemp S, Feely M, Hay A, Wild H, Cooper C 2007) Psychological factors and use of antiepileptic drugs: pilot work using an objective measure of adherence. Psychol Health Med 12 : 107 113.
28. Kintz P, Marescaux C, Mangin P 1995) Testing human hair for carbamazepine in epileptic patients: is hair investigation suitable for drug monitoring? Hum Exp Toxicol 14 : 812 815.
29. Landmark CJ, Rytter E, Johannessen SI 2007) Clinical use of antiepileptic drugs at a referral centre for epilepsy. Seizure 16 : 356 364.
30. Leppik IE, Cloyd JC, Sawchuk RJ, Pepin SM 1979) Compliance and variability of plasma phenytoin levels in epileptic patients. Ther Drug Monit 1 : 475 483.
31. Lisk DR, Greene SH 1985) Drug compliance and seizure control in epileptic children. Postgrad Med J 61 : 401 405.
32. Loiseau P, Marchal C 1988) Determinants of compliance in epileptic patients. Epilepsy Res Suppl 1 : 135 140.
33. Malone SA, Eadie MJ, Addison RS, Wright AW, Dickinson RG 2006) Monitoring salivary lamotrigine concentrations. J Clin Neurosci 13 : 902 907.
34. Mattson RH, Cramer JA, Collins JF 1988) Aspects of compliance: taking drugs and keeping clinic appointments. Epilepsy Res Suppl 1 : 111 117.
35. McAuliffe JJ, Sherwin AL, Leppik IE, Fayle SA, Pippenger CE 1977) Salivary levels of anticonvulsants: a practical approach to drug monitoring. Neurology 27 : 409 413.
36. McDonald HP, Garg AX, Haynes RB 2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288 : 2868 2879.
37. Mei Z, Williams J 1997) Simultaneous determination of phenytoin and carbamazepine in human hair by high-performance liquid chromatography. Ther Drug Monit 19 : 92 94.
38. Miles MV, Tang PH, Glauser TA, Ryan MA, Grim SA, Strawsburg RH, deGrauw TJ, Baumann RJ 2003) Topiramate concentration in saliva: an alternative to serum monitoring. Pediatr Neurol 29 : 143 147.
39. Miles MV, Tang PH, Ryan MA, Grim SA, Fakhoury TA, Strawsburg RH, DeGrauw TJ, Baumann RJ 2004) Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD). Ther Drug Monit 26 : 300 304.
40. Mitchell WG, Scheier LM, Baker SA 2000) Adherence to treatment in children with epilepsy: who follows "doctor's orders"? Epilepsia 41 : 1616 1625.
41. Mitchell AJ 2007) Adherence behaviour with psychotropic medication is a form of self-medication. Med Hypotheses 68 : 12 21.
42. Mucklow JC, Dollery CT 1978) Compliance with anticonvulsant therapy in a hospital clinic and in the community. Br J Clin Pharmacol 6 : 75 79.
43. Nichol MB, Venturini F, Sung JC 1999) A critical evaluation of the methodology of the literature on medication compliance. Ann Pharmacother 33 : 531 540.
44. Osterberg L, Blaschke T 2005) Adherence to medication. N Engl J Med 353 : 487 497.
45. Paschal AM, Ablah E, Wetta-Hall R, Molgaard CA, Liow K 2005) Stigma and safe havens: a medical sociological perspective on African-American female epilepsy patients. Epilepsy Behav 7 : 106 115.
46. Peterson GM, McLean S, Millingen KS 1984) A randomised trial of strategies to improve patient compliance with anticonvulsant therapy. Epilepsia 25 : 412 417.
47. Rochat P, Hallas J, Gaist D, Friis ML 2001) Antiepileptic drug utilization: a Danish prescription database analysis. Acta Neurol Scand 104 : 6 11.
48. Ryan M, Grim SA, Miles MV, Tang PH, Fakhoury TA, Strawsburg RH, deGrauw TJ, Baumann RJ 2003) Correlation of lamotrigine concentrations between serum and saliva. Pharmacotherapy 23 : 1550 1557.
49. Sander JW 2004) The use of antiepileptic drugs - principles and practice. Epilepsia 45 (Suppl 6 28 34.
50. Snodgrass SR, Vedanarayanan VV, Parker CC, Parks BR 2001) Pediatric patients with undetectable anticonvulsant blood levels: comparison with compliant patients. J Child Neurol 16 : 164 168.
51. Specht U, Elsner H, May TW, Schimichowski B, Thorbecke R 2003) Postictal serum levels of antiepileptic drugs for detection of noncompliance. Epilepsy Behav 4 : 487 495.
52. Stanaway L, Lambie DG, Johnson RH 1985) Non-compliance with anticonvulsant therapy as a cause of seizures. N Z Med J 98 : 150 152.
53. Steiner JF, Koepsell TD, Fihn SD, Inui TS 1988) A general method of compliance assessment using centralized pharmacy records: description and validation. Med Care 26 : 814 823.
54. Swarztrauber K, Dewar S, Engel J Jr. 2003) Patient attitudes about treatments for intractable epilepsy. Epilepsy Behav 4 : 19 25.
55. Takaki S, Kurokawa T, Aoyama T 1985) Monitoring drug noncompliance in epileptic patients: assessing phenobarbital plasma levels. Ther Drug Monit 7 : 87 91.
56. Thorbecke R 1988) Patients with epilepsy who discontinue treatment. Epilepsy Res Suppl 1 : 119 124.
57. Tokugawa K, Ueda K, Fujito H, Kurokawa T 1986) Correlation between the saliva and free serum concentration of phenobarbital in epileptic children. Eur J Pediatr 145 : 401 402.
58. Tomson T, Dahl M, Kimland E 2007) Therapeutic monitoring of antiepileptic drugs for epilepsy. Cochrane Database Syst Rev Published online: 24-January-2007; doi :.
59. Trostle JA, Hauser WA, Susser IS 1983) The logic of noncompliance: management of epilepsy from the patient's point of view. Cult Med Psychiatry 7 : 35 56.
60. Tsai JJ, Cheng TJ 1992) Status of follow-up among patients with epilepsy in epilepsy clinic. Jpn J Psychiatry Neurol 46 : 405 408.
61. Tsiropoulos I, Kristensen O, Klitgaard NA 2000) Saliva and serum concentration of lamotrigine in patients with epilepsy. Ther Drug Monit 22 : 517 521.
62. Vasudev A, Tripathi KD, Puri V 2002) Correlation of serum and salivary carbamazepine concentration in epileptic patients: implications for therapeutic drug monitoring. Neurol India 50 : 60 62.
63. Weber S, Beran RG 2004) A pilot study of compassionate use of Levetiracetam in patients with generalised epilepsy. J Clin Neurosci 11 : 728 731.
64. Wells S, Black R 2000) Cultural competency for health professionals. American Occupational Therapy Association, Bethesda, MD.
65. Williams J, Patsalos PN, Mei Z, Schapel G, Wilson JF, Richens A 2001) Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population. Ther Drug Monit 23 : 15 20.
66. Williams J, Myson V, Steward S, Jones G, Wilson JF, Kerr MP, Smith PE 2002) Self-discontinuation of antiepileptic medication in pregnancy: detection by hair analysis. Epilepsia 43 : 824 831.
67. Zysset T, Rudeberg A, Vassella F, Kupfer A, Bircher J 1981) Phenytoin therapy for epileptic children: evaluation of salivary and plasma concentrations and of methods of assessing compliance. Dev Med Child Neurol 23 : 66 75.